182 The Impact of the Act for the Development of Biotech and New Pharmaceuticals Industry on Firm Innovation in Taiwan ________. 2020. Public R&D spending and cross-sectional stock returns. Research Policy, 49 (1). doi: https://doi.org/10.1016/j.respol.2019.103887 Chen, Y. C. 2017. The impact of national health insurance policy on Taiwan pharmaceutical company for launching domestic new drug. Unpublished master’s thesis, Graduate Institute of Technology, Innovation & Intellectual Property Management, National Chengchi University, Taipei, Taiwan. （陳怡君， 全民健保藥價政策對臺灣本土研發新藥上市策略的影響，國立政治大學科 技管理與智慧財產研究所未出版之碩士論文，臺北，臺灣。） Cohen, W. M., Nelson, R. R., and Walsh, J. P. 2000. Protecting their intellectual assets: Appropriability conditions and why U.S. manufacturing firms patent (or not) (NBER Working Paper No. 7552). Cambridge, MA: National Bureau of Economic Research. Connolly, R. A., and Hirschey, M. 2005. Firm size and the effect of R&D on Tobin’s q. R&D Management, 35 (2): 217-223. Czarnitzki, D., Hanel, P., and Rosa, J. M. 2011. Evaluating the impact of R&D tax credits on innovation: A microeconometric study on Canadian firms. Research Policy, 40 (2): 217-229. Czarnitzki, D., and Hussinger, K. 2004. The link between R&D subsidies, R&D spending and technological performance (ZEW-Centre for European Economic Research Discussion Paper No. 04-056). Mannheim, Germany: Leibniz Center for European Economic Research. doi: http://dx.doi.org/10.2139/ssrn.575362 David, P. A., Hall, B. H., and Toole, A. A. 2000. Is public R&D a complement or substitute for private R&D? A review of the econometric evidence. Research Policy, 29 (4-5): 497-529. Dehej ia, R. H. , and Wahba, S. 2002. Propensi ty score-matching methods for nonexperimental causal studies. The Review of Economics and Statistics, 84 (1): 151-161. Duguet, E. 2004. Are R&D subsidies a substitute or a complement to privately funded R&D? An econometric analysis at the firm level. Revue D’Economie Politique, 114 (2): 245-274. Eisner, R., Albert, S. H., and Sullivan, M. A. 1984. The new incremental tax credit for R&D: Incentive or disincentive?. National Tax Journal, 37 (2): 171-183. Franzen, L. A., Rodgers, K. J., and Simin, T. T. 2007. Measuring distress risk: The effect of R&D intensity. The Journal of Finance, 62 (6): 2931-2967.
RkJQdWJsaXNoZXIy ODg3MDU=